Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2000

View Archived Issues

Intracel's phase III trial for bladder cancer approved by FDA

Vion updates clinical progress and development agreements

Guilford reacquires rights to Gliadel Wafer

MitoKor and UCSD receive BioSTAR grant for osteoarthritis research

LF-16-0687MS reduces brain edema and neurological severity scores in closed head trauma

ASA 2000: binding, functional and physicochemical properties of TRK-820 and TAN-684

Human studies confirm excellent safety and suitable pharmacokinetics of parecoxib

Phase II trial with EBV vaccine begins, triggering milestone payment to Aviron

Bradykinin B2 antagonist effective in rat model of head trauma

Remicade recommended for approval in Europe for broader application

CHEST 2000: anti-TNF MAb improves survival, reduces organ dysfunction in sepsis

FDA grants priority review status to Genelabs' NDA for new lupus therapy

Organon characterizes water-soluble general anesthetic advanced to early clinical trials

Update on proposed Novo Nordisk demerger

SmithKline Beecham's combination pediatric vaccine approved in E.U.

Novel immunosuppressants revealed by Japanese lab

Thiadiazole STAT6 activation inhibitors designed at Sumitomo

Dainippon describes new, water-soluble neutrophil elastase inhibitors

Bayer discloses sulfonamides and their use in the treatment of HCMV infections

U.S. patent covers new series of GH secretagogues from Novo Nordisk

Preparation and use of protease inhibitor series particularly useful in bone diseases

Novel treatments for labor pain revealed in recent patent by AstraZeneca

Caspase 3 inhibitors from Merck Frosst demonstrate antiischemic activity

Astex Technology and Janssen enter second research collaboration

Researchers discover potential new target for antidepressant drugs

Gaucher's disease therapy receives European orphan drug status

Inflammatory and autoimmune disease treatment enters phase I testing

Leukemia treatment designated an orphan drug in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...